Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
111,111,111
-
Number of holders
-
286
-
Total 13F shares, excl. options
-
83,909,168
-
Shares change
-
-119,971
-
Total reported value, excl. options
-
$6,154,095,452
-
Value change
-
-$12,964,425
-
Put/Call ratio
-
1.58%
-
Number of buys
-
125
-
Number of sells
-
-119
-
Price
-
$73.35
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q4 2022
363 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q4 2022.
NovoCure Ltd - Common Stock (NVCR) has 286 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 83,909,168 shares
of 111,111,111 outstanding shares and own 75.52% of the company stock.
Largest 10 shareholders include FMR LLC (15,736,679 shares), Capital World Investors (12,849,519 shares), VANGUARD GROUP INC (9,547,336 shares), BAILLIE GIFFORD & CO (8,863,842 shares), Capital International Investors (7,951,648 shares), BlackRock Inc. (7,605,656 shares), STATE STREET CORP (2,237,650 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,168,431 shares), Nordwand Advisors, LLC (1,515,000 shares), and GEODE CAPITAL MANAGEMENT, LLC (1,350,341 shares).
This table shows the top 286 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.